Understanding Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis (FSGS) represents a leading cause of nephrotic syndrome and end-stage kidney disease worldwide, characterized by scarring in parts of the glomeruli—the tiny filtering units within the kidneys. In FSGS, only some glomeruli (focal) are affected, and the damage occurs in segments of these structures (segmental), leading to protein leakage into the urine, swelling due to fluid retention, low blood albumin levels, and progressive loss of kidney function. Primary FSGS, the focus of recent trials, stems from intrinsic podocyte injury rather than secondary causes like obesity or infections.

In Europe, FSGS qualifies as an orphan disease, affecting approximately 2.6 per 10,000 individuals according to European Medicines Agency (EMA) data. It accounts for 20-30% of adult nephrotic syndrome cases and up to 40% in some biopsy series, with higher incidence among certain ethnic groups. Without effective treatments, up to 50% of patients progress to dialysis within 5-10 years, imposing significant burdens on healthcare systems and patients' quality of life. Current management relies on renin-angiotensin system blockers, immunosuppression like corticosteroids or calcineurin inhibitors, and supportive care, but remission rates remain low at 20-50%.

The disease's rarity and complexity have spurred academic collaborations across European universities, from Heidelberg to Barcelona, emphasizing the need for precision therapies targeting underlying mechanisms.

The Pathogenic Role of TRPC6 in FSGS

Transient Receptor Potential Canonical 6 (TRPC6) is a calcium-permeable ion channel predominantly expressed in podocytes, the epithelial cells forming the glomerular filtration barrier. In FSGS, TRPC6 becomes hyperactive due to genetic mutations (seen in 10-15% of familial cases) or upregulation from circulating factors, causing excessive calcium influx. This disrupts podocyte cytoskeleton, foot process effacement, and slit diaphragm integrity, initiating proteinuria and sclerosis.

Preclinical models demonstrate that TRPC6 inhibition preserves podocyte viability and reduces proteinuria, positioning it as a promising therapeutic target. Gain-of-function TRPC6 variants are linked to adult-onset FSGS, highlighting its relevance in sporadic cases too. European research, including ERC-funded projects like CureFSGS, explores immune-mediated podocyte injury intersecting with TRPC6 pathways, underscoring the continent's leadership in glomerular disease genetics.

BI 764198: A Selective TRPC6 Inhibitor

BI 764198, also known as apecotrep, is an oral, small-molecule inhibitor developed by Boehringer Ingelheim with high selectivity for TRPC6 over other channels. Phase 1 studies confirmed its safety, pharmacokinetics, and target engagement in healthy volunteers and Japanese subjects. Granted EMA Orphan Drug Designation for FSGS, it aims to be the first podocyte-specific therapy.

Unlike broad immunosuppressants, BI 764198 directly addresses podocyte calcium dysregulation, potentially halting disease progression at its root.

Design and Methodology of the Phase 2 Trial

The pivotal study (NCT05213624) was a multicenter, double-blind, placebo-controlled, randomized phase 2 trial enrolling 67 adults with primary FSGS and persistent proteinuria despite stable therapy. Participants had eGFR 30-90 mL/min/1.73m² and UPCR ≥1.5 g/g. Randomized 2:2:2:3 to 20mg, 40mg, 80mg BI 764198 or placebo once daily for 12 weeks, with a 4-week run-in.

Primary endpoints: proportion achieving ≥25% UPCR reduction from baseline at week 12; relative UPCR change. Secondary: absolute UPCR changes, protein excretion. Conducted across 10 countries including robust European sites like Universitätsklinikum Heidelberg (Germany), Hospital Clínic de Barcelona (Spain), and Addenbrooke's Hospital (UK).Explore higher education opportunities in Europe

• Exclusion: secondary FSGS, recent immunosuppressants.
• Follow-up: safety to week 13.
• Trial registration: ClinicalTrials.gov NCT05213624.

Key Efficacy Results from the Lancet Publication

Published January 27, 2026, in The Lancet, results showed dose-dependent proteinuria reductions.Read the full Lancet article The 20mg arm achieved a 40% mean UPCR reduction vs placebo, with odds ratio (OR) 10.0 (95% CI 1.6-118.1; p=0.027) for ≥25% response. Overall, 44% in low-dose vs 10% placebo responded.

Higher doses showed trends but less statistical power due to smaller numbers. In TRPC6 mutation carriers (n=7), 100% response in treated vs none in placebo. eGFR stabilized across arms.

These findings mark the first clinical proof-of-concept for podocyte-targeted therapy in FSGS.

Safety Profile and Tolerability

BI 764198 was well-tolerated, with adverse events similar to placebo (e.g., infections, GI issues). No dose-dependent increases in serious events; low discontinuation (5%). No podocyte toxicity signals, supporting long-term use.View trial details on ClinicalTrials.gov

• Common AEs: headache (15%), nausea (12%) – mostly mild.
• Serious AEs: 8% drug vs 10% placebo.
• Renal function: no acute declines.

European Contributions to the Trial and Research Landscape

Europe played a central role, with sites in Belgium, France, Germany, Italy, Spain, and UK enrolling ~30% of patients. Academic centers like Medizinische Hochschule Hannover and Policlinico S. Orsola-Malpighi drove recruitment and data quality. EMA's orphan designation accelerates potential approval.

European nephrology networks, including collaborations with universities, advance FSGS genomics and trials. For researchers eyeing clinical studies, opportunities abound in glomerular disease.Browse research jobs at leading European institutions.

Implications for FSGS Management in Europe

If phase 3 succeeds, BI 764198 could transform care, offering a steroid-sparing option with better remission odds. Current guidelines emphasize RAS inhibition first-line, but add-ons like this target unmet needs. Cost-effectiveness in orphan context will rely on EMA fast-track.

Stakeholders: patients gain hope; payers, reduced dialysis burden; clinicians, precision tools. Balanced views note need for long-term eGFR data.

Phase 3 Trial and Future Outlook

Pivotal phase 3 (NCT07220083) randomizes 286 patients to BI 764198 vs placebo over 104 weeks, focusing on eGFR slope. Recruiting globally, including Europe.Phase 3 trial information

Boehringer explores other proteinuric diseases. Combinatorial therapies with SGLT2i or endothelin antagonists loom.Boehringer press release Outlook: potential 2028 approval.

Career Opportunities in Nephrology Research

This trial exemplifies translational research from bench (TRPC6 discovery) to bedside, involving academics like Prof. Howard Trachtman (University of Michigan) and European PIs. Aspiring researchers can contribute via clinical trials, genetics.Clinical research jobs abound; craft your academic CV for success. Platforms like AcademicJobs connect to /higher-ed-jobs in Europe.

• Postdoc roles in podocyte biology.
• Faculty positions in renal medicine.
• Industry-academia partnerships.

Conclusion: A New Era for FSGS Therapy

The Lancet phase 2 trial of BI 764198 heralds podocyte-targeted innovation for FSGS, with strong European footprint. While challenges like progression data persist, this advances precision nephrology. Explore rate my professor, higher ed jobs, career advice, university jobs, or post a job to engage further.